Publications

Detailed Information

Molecular characterization and prognostic significance of FLT3 in CML progression

Cited 10 time in Web of Science Cited 10 time in Scopus
Authors

Kim, Kyung Im; Park, Juwon; Ahn, Kwang-Sung; Won, Nam-Hee; Shin, Wan Gyoon; Oh, Jung Mi; Yoon, Sung-Soo; Kim, Byoung Kook

Issue Date
2010-08
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
Citation
LEUKEMIA RESEARCH; Vol.34 8; 995-1001
Keywords
Chronic myelogenous leukemia (CML)Fms-related tyrosine kinase 3 (FLT3)ImatinibDisease progressionResistance
Abstract
To characterize the molecular mechanisms involved in the transition from the chronic phase to blast crisis in chronic myelogenous leukemia (CML), gene expression profiles of leukemic cells from patients in the chronic and blast crisis phases were analyzed using an 8.7K cDNA chip and real-time PCR. A transient transfection analysis was conducted to evaluate the role of FLT3, which was significantly upregulated in the blast crisis patients. Abl and c-Kit induction was detected in K562 cells transfected with FLT3 cDNA (K562/FLT3), and Abl and c-Kit levels were reduced in K562/FLT3 cells transfected with FLT3-siRNA (K562/FLT3-siRNA). The induction of FLT3 in CML cells attenuated imatinib-induced apoptosis. The opposite effect was observed in K562/FLT3-siRNA cells. An increased level of cleaved PARP and decreased level of pro-caspase 3 were noted when K562/FLT3-siRNA cells were treated with imatinib. These findings indicate that FLT3 is associated with disease progression, despite imatinib therapy. These results may help in the prediction of disease progression in CML patients and the development of more appropriate therapeutic modalities. (C) 2009 Elsevier Ltd. All rights reserved.
ISSN
0145-2126
Language
English
URI
https://hdl.handle.net/10371/76468
DOI
https://doi.org/10.1016/j.leukres.2009.11.008
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share